2025-10-03 - Analysis Report
Okay, here's an analysis of TransMedics Group Inc. (TMDX) based on the provided data.

## TMDX (Transmedics Group Inc.) Analysis

**Company Overview:** TransMedics Group Inc. is a medical technology company focused on developing and delivering innovative organ preservation systems for transplantation.

---

### 1. Performance vs. S&P 500 (VOO)

*   **TMDX Cumulative Return:** 184.66%
*   **VOO Cumulative Return:** 72.81%
*   **Spread (Current):** 111.85%
*   **Spread Range:** Max: 247.2, Min: -74.5
*   **Relative Spread Position:** 57.9 (Indicates the current spread is at the 57.9th percentile of its historical range.)

**Analysis:**  TMDX has significantly outperformed the S&P 500 (VOO) over the tracked period. The current spread of 111.85% is positive, but the Relative Spread Position of 57.9 suggests that, while TMDX is outperforming, its outperformance is not at the very top of its historical range relative to the S&P 500.

**Alpha, Beta Analysis:**

| Year       | CAGR    | MDD   | Alpha  | Beta | Cap(B) |
| ---------- | ------- | ----- | ------ | ---- | ------ |
| 2019-2021 | -18.0%  | 83.5% | -61.0% | -0.0 | 0.7    |
| 2020-2022 | 94.0%   | 83.5% | 95.0%  | 0.0  | 2.1    |
| 2021-2023 | 65.0%   | 80.5% | 64.0%  | 0.1  | 2.7    |
| 2022-2024 | 130.0%  | 85.5% | 109.0% | 0.1  | 2.1    |
| 2023-2025 | 105.0%  | 85.5% | 43.0%  | 0.3  | 3.9    |

*   **CAGR:** Shows strong growth in recent periods (2020-2025).
*   **MDD:** Consistently high, indicating significant volatility and downside risk.
*   **Alpha:**  Generally positive and high, suggesting TMDX is generating returns independent of the market. Alpha decreased significantly in the most recent period (2023-2025).
*   **Beta:** Low, suggesting the stock is not highly correlated with the market. The Beta has increased in the most recent period.
*   **Cap(B):** Increasing capitalization.

### 2. Recent Stock Price Movement

*   **Current Price:** 112.69
*   **Last Market Data:** Price: 116.07, Previous Close: 114.89, Change: 1.03
*   **5-Day Moving Average:** 114.96
*   **20-Day Moving Average:** 113.68
*   **60-Day Moving Average:** 116.44

**Analysis:** The current price (112.69) is below the 5-day, 20-day, and 60-day moving averages. The recent market data shows a positive change, indicating a slight upward movement. The price change from the last market data suggests a potential rebound.

### 3. Market Risk Indicators

*   **MRI:** 0.9 (High Investment Recommended)
*   **RSI:** 56.00 (Neutral)
*   **PPO:** -0.08 (Slightly Bearish)
*   **Hybrid Signal:** "cash_0%_Buy 100% of cash (1 shares - Very Safe - MRI:0.90)"
*   **Recent (20-day) Relative Spread Change:** -9.5 (Indicates recent underperformance relative to the S&P 500)
*   **Expected Return:** 53.0% (Long-term, expected outperformance vs. S&P 500)

**Analysis:**

*   The MRI indicates a generally favorable investment environment.
*   The RSI suggests a neutral condition, neither overbought nor oversold.
*   The PPO is slightly negative, suggesting a minor bearish trend in momentum.
*   The hybrid signal strongly recommends a buy position.
*   The negative recent relative spread change (-9.5) indicates some short-term underperformance relative to the benchmark. The last price movement is positive, suggesting a possible reversal.
*   The 53% expected return indicates a significant long-term upside potential.

### 4. Recent News & Significant Events

*   **Lowering Target Price (Argus Research):** A negative signal, potentially causing downward pressure.
*   **Strong Growth Stock (Zacks):** A positive signal, suggesting potential for future gains.
*   **Undervalued (Simply Wall St.):**  A positive signal, indicating potential for price appreciation.
*   **Partnership with Mercedes-Benz:**  Very positive news. This signals innovation, expansion, and potential revenue growth. This is a significant development for organ transportation.

**Analysis:**  The news is mixed. The lowered target price is a concern, but the other articles highlight growth potential and undervaluation. The partnership with Mercedes-Benz is particularly noteworthy and suggests strategic expansion.

### 4-2. Analyst Opinions

*   **Consensus:** Buy (~1.82 on a 1-5 scale)
*   **Opinions:** 9 analysts
*   **Target Price:** Average: $140.67, High: $170.00, Low: $114.00

**Analysis:** Analyst sentiment is generally positive, with a "Buy" consensus and an average target price significantly above the current price (112.69).

### 5. Recent Earnings Analysis

| Date       | EPS  | Expected EPS |
| ---------- | ---- | ------------- |
| 2025-07-30 | 0.92 | 0.48          |
| 2025-05-08 | 0.70 | 0.29          |
| 2025-02-27 | 0.19 | 0.22          |
| 2024-10-28 | 0.12 | 0.29          |
| 2024-07-31 | 0.35 | 0.21          |

**Analysis:** TransMedics has consistently beaten EPS estimates in recent quarters, except for 2025-02-27 and 2024-10-28. This suggests strong performance and good management.

### 6. Financial Information

**Revenue and Profitability:**

| Quarter    | Revenue   | Profit Margin |
| ---------- | --------- | ------------- |
| 2025-06-30 | \$0.16B  | 61.38%        |
| 2025-03-31 | \$0.14B  | 61.47%        |
| 2024-12-31 | \$0.12B  | 59.21%        |
| 2024-09-30 | \$0.11B  | 55.94%        |
| 2024-06-30 | \$0.11B  | 60.59%        |

**Capital and Profitability:**

| Quarter    | Equity    | ROE       |
| ---------- | --------- | --------- |
| 2025-06-30 | \$0.32B  | 10.97%    |
| 2025-03-31 | \$0.27B  | 9.64%     |
| 2024-12-31 | \$0.23B  | 3.00%     |
| 2024-09-30 | \$0.21B  | 2.01%     |
| 2024-06-30 | \$0.19B  | 6.42%     |

**Analysis:**

*   **Revenue:** Steadily increasing, indicating strong growth.
*   **Profit Margin:** Consistently high, demonstrating efficient operations and pricing power.
*   **Equity:** Growing, reflecting increased financial strength.
*   **ROE:**  Generally increasing, indicating improved profitability relative to equity.

### 7. Overall Summary

TransMedics (TMDX) presents a mixed but overall positive picture:

*   **Strengths:**
    *   Significant outperformance vs. S&P 500 in the past, but alpha is decreasing in the short-term and recent underperformance.
    *   Strong revenue growth and high-profit margins.
    *   Consistent EPS beats.
    *   Positive analyst sentiment with a "Buy" consensus and target prices significantly above the current price.
    *   Strategic partnership with Mercedes-Benz, indicating innovation and expansion.
    *   High MRI suggesting a favorable investment environment.
    *   High long-term expected return.
*   **Weaknesses/Risks:**
    *   High MDD, indicating significant volatility.
    *   Recent downward revision of the target price by one analyst.
    *   Recent underperformance relative to the S&P 500 (negative 20-day relative spread change).
    *   Current price is below the moving averages.

**Conclusion:**

TMDX appears to be a potentially attractive investment due to its strong growth, high profitability, positive analyst sentiment, and strategic partnerships. However, the high volatility and recent negative news and price action warrant caution.

**Recommendation:**

A buy position is supportable based on the hybrid signal (with a small number of shares), analyst consensus, and long-term growth potential. But, risk management is important. Monitor the stock closely for any further negative news or price declines. Consider using stop-loss orders to limit potential losses due to volatility. The analyst target price of ~$140 is a good guideline to when you may want to re-evaluate the investment.
